Literature DB >> 24567009

Off-label use of drugs in children.

Daniel A Frattarelli, Jeffrey L Galinkin, Thomas P Green, Timothy D Johnson, Kathleen A Neville, Ian M Paul, John N Van Den Anker.   

Abstract

The passage of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act has collectively resulted in an improvement in rational prescribing for children, including more than 500 labeling changes. However, off-label drug use remains an important public health issue for infants, children, and adolescents, because an overwhelming number of drugs still have no information in the labeling for use in pediatrics. The purpose of off-label use is to benefit the individual patient. Practitioners use their professional judgment to determine these uses. As such, the term "off-label" does not imply an improper, illegal, contraindicated, or investigational use. Therapeutic decision-making must always rely on the best available evidence and the importance of the benefit for the individual patient.

Entities:  

Keywords:  adolescents; children; infants; off-label drug use; pediatrics; pharmaceuticals; prescribing

Mesh:

Year:  2014        PMID: 24567009     DOI: 10.1542/peds.2013-4060

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  90 in total

Review 1.  Pharmacotherapy for Seizures in Neonates with Hypoxic Ischemic Encephalopathy.

Authors:  Elissa Yozawitz; Arthur Stacey; Ronit M Pressler
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022

2.  Off-label and unlicensed drug treatments in Neonatal Intensive Care Units: an Italian multicentre study.

Authors:  Laura Cuzzolin; Rocco Agostino
Journal:  Eur J Clin Pharmacol       Date:  2016-01       Impact factor: 2.953

3.  Pediatric off-label use of psychotropic drugs approved for adult use in Japan in the light of approval information regarding pediatric patients in the United States: a study of a pharmacy prescription database.

Authors:  Nanae Tanemura; Maika Asawa; Mayuko Kuroda; Tsuyoshi Sasaki; Yoshiaki Iwane; Hisashi Urushihara
Journal:  World J Pediatr       Date:  2018-11-30       Impact factor: 2.764

4.  Primary Care Physician Attitudes and Intentions Toward the Use of HIV Pre-exposure Prophylaxis in Adolescents in One Metropolitan Region.

Authors:  Tanya L Kowalczyk Mullins; Caitlyn R Idoine; Gregory D Zimet; Jessica A Kahn
Journal:  J Adolesc Health       Date:  2018-12-19       Impact factor: 5.012

Review 5.  Paediatric extrapolation: A necessary paradigm shift.

Authors:  Cécile Ollivier; Yeruk Lily Mulugeta; Lucia Ruggieri; Agnes Saint-Raymond; Lynne Yao
Journal:  Br J Clin Pharmacol       Date:  2018-12-18       Impact factor: 4.335

6.  Off-label Medications Use in the Eastern Province of Saudi Arabia: The Views of General Practitioners, Pediatricians, and Other Specialists.

Authors:  Zainab AbuAlsaud; Dhfer Alshayban; Royes Joseph; Faheem Hyder Pottoo; Jisha Myalil Lucca
Journal:  Hosp Pharm       Date:  2018-12-07

7.  Acetylcysteine and Acetaminophen Overdose: The Many Shades of Gray.

Authors:  Peter A Chyka
Journal:  J Pediatr Pharmacol Ther       Date:  2015 May-Jun

8.  HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.

Authors:  Tanya L Kowalczyk Mullins; Gregory Zimet; Michelle Lally; Jiahong Xu; Sarah Thornton; Jessica A Kahn
Journal:  AIDS Patient Care STDS       Date:  2017-12       Impact factor: 5.078

9.  Changing patterns of alpha agonist medication use in children and adolescents 2009-2011.

Authors:  Alexander G Fiks; Stephanie L Mayne; Lihai Song; Jennifer Steffes; Weiwei Liu; Banita McCarn; Benyamin Margolis; Alan Grimes; Edward Gotlieb; Russell Localio; Michelle E Ross; Robert W Grundmeier; Richard Wasserman; Laurel K Leslie
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-04-28       Impact factor: 2.576

10.  Joint Statement on Pediatric Education at Schools of Pharmacy.

Authors:  Christina L Cox; Timothy J Todd; Lisa Lubsch; Kristin C Klein; William A Prescott; Chad A Knoderer; Peter N Johnson; Rachel Meyers; Justin W Cole; Joseph M LaRochelle; Mary A Worthington; Katherine Smith
Journal:  Am J Pharm Educ       Date:  2020-08       Impact factor: 2.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.